The influence of protein depletion and repletion on the excretion of uric acid, urea, creatinine and free arginine as well as on the activities of xanthine dehydrogenase and arginase in Japanese quail was studied. Adult cockerels normally fed until the age of 42 days were kept on a protein free diet for 21 days and subsequently for 14 days on the previous normal diet. The control group was fed normal diet for the whole time. In 1-5 days intervals the enzyme activities and the N-metabolites in 24 hours excreta were determined. Protein free diet feeding evoked rapid (in term of 8-9 days) diminution of the excretion of N-metabolites, as well as of the xanthine dehydrogenase activity up to the fourth-tenth part of the initial values. The arginase activity was not influenced by this treatment. Body mass decreased by 36%. Returning to the normal protein feeding reverse the values of observed parameters to their initial levels within 8-9 days. It was concluded that changes in excreted N-metabolites caused by protein free feeding were rapid and recoverable by returning to normal diet.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/17450399309386102 | DOI Listing |
Discov Oncol
January 2025
Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, Jiangsu, China.
This study aims to investigate the expression of seven cancer testis antigens (MAGE-A1, MAGE-A4, MAGE-A10, MAGE-A11, PRAME, NY-ESO-1 and KK-LC-1) in pan squamous cell carcinoma and their prognostic value, thus assessing the potential of these CTAs as immunotherapeutic targets. The protein expression of these CTAs was evaluated by immunohistochemistry in 60 lung squamous cell carcinoma (LUSC), 62 esophageal squamous cell carcinoma (ESCA) and 62 head and neck squamous cell carcinoma (HNSC). The relationship between CTAs expression and progression-free survival (PFS) was assessed.
View Article and Find Full Text PDFCytotherapy
January 2025
Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Electronic address:
Background/aims: Human mesenchymal stromal cells (hMSC) are multipotent adult cells commonly used in regenerative medicine as advanced therapy medicinal products. The expansion of these cells in xeno-free supplements is highly encouraged by regulatory agencies due to safety concerns. However, the number of supplements with robust performance and consistency for hMSC expansion are limited.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Electrical Electronical Engineering, Yaşar University, Bornova, İzmir, Turkey.
We aimed to build a robust classifier for the MGMT methylation status of glioblastoma in multiparametric MRI. We focused on multi-habitat deep image descriptors as our basic focus. A subset of the BRATS 2021 MGMT methylation dataset containing both MGMT class labels and segmentation masks was used.
View Article and Find Full Text PDFPurpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease.
Methods: Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), both comprising a 48-week core phase and an optional open-label extension. Changes from baseline in systolic and diastolic BP (SBP and DBP), fasting plasma glucose (FPG), and glycated hemoglobin (HbA) were evaluated during osilodrostat treatment in patients with/without hypertension or diabetes at baseline.
Sci Rep
January 2025
Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are effective in adjuvant therapy and which treatment is effective as first-line metastatic therapy. This retrospective, multicenter study included 120 patients diagnosed with stage IIIB-IIID melanoma receiving both adjuvant and first-line metastatic treatment between 2007 and 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!